I D Arnott
Overview
Explore the profile of I D Arnott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
427
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jenkinson P, Plevris N, Siakavellas S, Lyons M, Arnott I, Wilson D, et al.
J Crohns Colitis
. 2020 Aug;
14(9):1241-1247.
PMID: 32840295
Background: The use of biologic therapy for Crohn's disease [CD] continues to evolve, however, the effect of this on the requirement for surgery remains unclear. We assessed changes in biologic...
2.
Plevris N, Chuah C, Allen R, Arnott I, Brennan P, Chaudhary S, et al.
J Crohns Colitis
. 2019 Feb;
13(9):1111-1120.
PMID: 30768123
Background & Aims: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The aims of this study were...
3.
Capsule endoscopy in suspected small bowel Crohn's disease - Is it worth repeating a negative study?
Robertson A, Yung D, Arnott I, Plevris J, Koulaouzidis A
Dig Liver Dis
. 2018 Nov;
51(1):174-176.
PMID: 30448458
No abstract available.
4.
Paterson H, Arnott I, Nicholls R, Clark D, Bauer J, Bridger P, et al.
Colorectal Dis
. 2014 Nov;
17(4):329-34.
PMID: 25359603
Aim: Symptomatic diverticular disease (DD) may be increasing in incidence in western society particularly in younger age groups. This study aimed to describe hospital admission rates and management for DD...
5.
Kennedy N, Kalla R, Warner B, Gambles C, Musy R, Reynolds S, et al.
Aliment Pharmacol Ther
. 2014 Oct;
40(11-12):1313-23.
PMID: 25284134
Background: Thiopurines (azathioprine and mercaptopurine) remain integral to most medical strategies for maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). Indefinite use of these drugs is tempered by...
6.
Jones G, Kennedy N, Lees C, Arnott I, Satsangi J
Aliment Pharmacol Ther
. 2014 Jul;
40(3):323.
PMID: 25040750
No abstract available.
7.
Jones G, Kennedy N, Lees C, Arnott I, Satsangi J
Aliment Pharmacol Ther
. 2014 Apr;
39(11):1253-65.
PMID: 24738574
Background: Post-operative recurrence of Crohn's disease is an important management challenge, with 2-year recurrence rates defined by clinical, endoscopic and radiological parameters of up to 77%, 64% and 49%. Clinical...
8.
Ghosh S, Dahele A, Drummond H, Hoque S, Humphreys K, Arnott I
Methods Mol Med
. 2011 Mar;
41:257-77.
PMID: 21374445
Studies of intestinal mucosal immunity and inflammation are limited by the relative inaccessibility of most of the small intestine. Any new method of studying mucosal immunity and inflammation in patients...
9.
Ho G, Lee H, Brydon G, Ting T, Hare N, Drummond H, et al.
Am J Gastroenterol
. 2009 Mar;
104(3):673-8.
PMID: 19262524
Objectives: Calprotectin is a granulocyte neutrophil-predominant cytosolic protein. Fecal concentrations are elevated in intestinal inflammation and may predict relapse in quiescent inflammatory bowel disease. We aim to investigate fecal calprotectin...
10.
Ho G, Mowat A, Potts L, Cahill A, Mowat C, Lees C, et al.
Aliment Pharmacol Ther
. 2009 Feb;
29(5):527-34.
PMID: 19183339
Background: Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD). Aims: To evaluate the efficacy and safety of adalimumab on...